Evidence map›Paper›PMID 19484406›Full record

ArticleJournal of neuro-oncology2009

Cognitive effects of pegylated interferon in individuals with primary brain tumors.

Mercedes D Dickinson, Christopher D Barr, Merrill Hiscock, Christina A Meyers

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Mercedes D DickinsonDepartment of Neurology, Division of Neuropsychology, Medical College of Wisconsin, 9200 W. Wisconsin Ave., Milwaukee, WI, 53226, USA. mdickinson@mcw.edu.
Christopher D BarrTexas Institute for Measurement, Evaluation, and Statistics, University of Houston, 100 TLCC Annex, Houston, TX, 77204-6022, USA.
Merrill HiscockDepartment of Psychology, University of Houston, 126 Heyne Building, Houston, TX, 77204-5022, USA.
Christina A MeyersNeuro-Oncology Unit 431, M.D. Anderson Cancer Center, P.O. Box 301402, Houston, TX, 77230-1402, USA.
University of Houston · USMedical College of Wisconsin · USThe University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cognitive changes associated with interferon treatment include impaired verbal memory, attention, processing speed, and executive functioning. Pegylated interferon is a relatively new, long-lasting form of interferon alpha, but data regarding its cognitive effects in brain tumor patients are limited. Participants in this study were 35 primary brain tumor patients who received pegylated interferon at tumor recurrence. A neuropsychological battery assessed verbal memory, executive functioning, attention, information processing speed, and language functioning. Individual growth curve analyses were used to estimate cognitive change throughout treatment with interferon. Results revealed performance declined on a task of psychomotor speed and upper extremity dexterity. Although decline in a few tests was found, its degree may have been reduced because individuals were tested after tumor recurrence where a substantial amount of cognitive change had already potentially occurred due to surgery, radiation therapy, and chemotherapy. Thus, participants may not have been starting at their baseline cognitive status and the potential neurotoxic effects of interferon may have been obscured by prior treatments. An alternative explanation, however, is that treatment with pegylated interferon did not produce further impairment and patients experienced stability in their cognitive functioning.

Indexed as

AdultAntineoplastic AgentsAntiviral AgentsBrain NeoplasmsCognitionDrug CarriersFemaleHumansInterferon-alphaInterferon alpha-2MaleNeuropsychological TestsPolyethylene GlycolsPrognosisRecombinant ProteinsSurvival RateAntineoplastic AgentsAntiviral AgentsDrug CarriersInterferon-alphaInterferon alpha-2peginterferon alfa-2aPolyethylene GlycolsRecombinant Proteins

Identifiers

PMID19484406
OpenAlexW2033436096

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.